Quantification of amyloid PET for future clinical use: a state-of-the-art review
Hugh Pemberton(Queen Mary University of London), Gill Farrar(General Electric (Spain)), David Vállez García(Pasqual Maragall Foundation), Isadora Lopes Alves(Amsterdam University Medical Centers), Andrew Stephens(Piramal (Germany)), Valentina Garibotto(University of Geneva), Christopher Buckley(Amersham Hospital), Santiago Bullich, Lyduine E. Collij(Lund University), Mahnaz Shekari(Universitat Pompeu Fabra), Gemma Salvadó(Lund University), Fiona Heeman(Amsterdam University Medical Centers), Frederik Barkhof(National Hospital for Neurology and Neurosurgery), Juan Domingo Gispert(Lund University), Mark Battle(Lund University), Ariane Bollack(University College London)
Cited by 211
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Consistent resting-state networks across healthy subjects
|Proceedings of the National Academy of Sciences|2006|4.4k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k